The impact of CYP3A5 , NR1I2 , and POR polymorphisms on tacrolimus dose-adjusted concentration and clinical outcomes in adult allogeneic haematopoietic stem cell transplantation

Polymorphisms in genes related to drug-metabolising enzymes may affect tacrolimus exposure. This study aimed to assess the influence of , , and polymorphisms on tacrolimus pharmacokinetics and outcomes in allogeneic haematopoietic stem cell transplantation (HSCT).Forty-six adult patients receiving o...

Full description

Saved in:
Bibliographic Details
Published in:Xenobiotica 2025-01, p.1-9
Main Authors: Gao, Yuan, Ma, Jingjing
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polymorphisms in genes related to drug-metabolising enzymes may affect tacrolimus exposure. This study aimed to assess the influence of , , and polymorphisms on tacrolimus pharmacokinetics and outcomes in allogeneic haematopoietic stem cell transplantation (HSCT).Forty-six adult patients receiving oral tacrolimus at an initial dose of 0.03 mg/kg/day for acute graft versus host disease (GVHD) prophylaxis after allogeneic HSCT were enrolled in this retrospective study. Genetic polymorphisms were detected in relation to concentration/dose (C/D) ratios of tacrolimus and the incidence of acute GVHD and acute kidney injury (AKI).The genotype and co-administration of voriconazole were significantly associated with increased C/D ratios of tacrolimus (   T, and concomitant use of voriconazole are important determinants affecting tacrolimus pharmacokinetics. Moreover, allele and younger age are independent risk factors for II-IV acute GVHD in HSCT recipients.
ISSN:0049-8254
1366-5928
1366-5928
DOI:10.1080/00498254.2024.2448967